Purpose Everolimus, an oral inhibitor of the mammalian target of rapamycin, has shown
antitumor activity. in gastric cancer in preclinical and phase l studies. This phase ll study
evaluated the efficacy and safety of everolimus in pretreated patients with advanced gastric
cancer. Patients and Methods; Patients with advanced gastric cancer vvho experienced
progression despite prior chemotherapy received everolimus 10 mg orally daily until
disease progression or study discontinuation. The primary end point was disease control …